Abstract: The OLA-guided therapy group had pre-ART peripheral blood mononuclear cells evaluated for drug resistance to
non-nucleoside reverse transcriptase inhibitor (
NNRTI) at codons
Lys103Asn,
Tyr181Cys,
Gly190Ala, and to lamivudine at
Met184Val, and when at least one drug-resistant codon was detected in a participant's pre-ART specimen, clinicians were directed to prescribe
protease inhibitor-based second-line ART.
Method: Peripheral blood mononuclear cells were evaluated for
NNRTI and
NRTI drug resistance mutations,
K103N,
Y181C,
G190A, and